Will Novo Nordisk Get Lift From Gut-Brain Axis?

Victoza Data In Alzheimer's May Signal Opportunity For GLP-1 Class.

07 Apr 2020

• By Sten Stovall

Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.

Gut - Brain — Evidence increasingly links gut and brain health • Source: Shutterstock

Will Novo Nordisk Get Lift From Gut-Brain Axis?

Victoza Data In Alzheimer's May Signal Opportunity For GLP-1 Class.

More from Business

More from Scrip